Ulrik Dolberg Anderson1, Maya Jälmby2, Marijke M Faas3, Stefan R Hansson2. 1. Section of Obstetrics and Gynecology, Department of Clinical Sciences Lund, Lund University, Sweden; Skåne University Hospital, Malmö/Lund, Sweden. Electronic address: ulrik.dolberg_anderson@med.lu.se. 2. Section of Obstetrics and Gynecology, Department of Clinical Sciences Lund, Lund University, Sweden; Skåne University Hospital, Malmö/Lund, Sweden. 3. Department of Pathology and Medical Biology and Department of Obstetrics and Gynecology, University of Groningen and University Medical Center Groningen, The Netherlands.
Abstract
OBJECTIVE: The aim of this study was to investigate how maternal cell-free fetal hemoglobin and heme impact the scavenger enzyme systems Hemopexin and Heme Oxygenase-1 in patients with preeclampsia (PE). The secondary aims were to evaluate these proteins as biomarkers for severity of the clinical manifestation i.e. hypertension, in early- and late onset PE. MATERIAL AND METHODS: Plasma samples taken within the last 24 h before delivery from 135 patients were analyzed, 89 PE and 46 normal pregnancies. All samples were analyzed for cell-free fetal hemoglobin (HbF), heme, hemopexin enzymatic activity (Hx activity), hemopexin concentration (Hx), and heme oxygenase 1 concentration (HO-1). Logistic regression analysis with ROC-curve analysis was performed to evaluate the possible use as biomarkers for preeclampsia. RESULTS: There were significantly higher levels of HbF (p = 0.01) and heme (0.01) but significantly lower Hx activity (p = 0.02), Hx (p < 0.0001) and HO-1 (p = 0.03) in PE plasma as compared to plasma of normal pregnancies. The Hx activity was significantly inversely correlated (p = 0.04) to the diastolic blood pressure. The HO-1 concentration was significantly inversely correlated to both the systolic and diastolic blood pressure (p = 0.01 and p = 0.003). ROC-curve analysis showed a combined detection rate for these biomarkers of 84% at 10% false positive rate. CONCLUSIONS: Increased maternal plasma levels of heme and HbF in PE are associated with decreased HO-1 and hemopexin protein levels as well as reduced hemopexin activity. By measuring the consumption of the scavenger protein Hx, and the proteins in the Hb degradation system, clinical information about the dynamics of the disease can be obtained.
OBJECTIVE: The aim of this study was to investigate how maternal cell-free fetal hemoglobin and heme impact the scavenger enzyme systems Hemopexin and Heme Oxygenase-1 in patients with preeclampsia (PE). The secondary aims were to evaluate these proteins as biomarkers for severity of the clinical manifestation i.e. hypertension, in early- and late onset PE. MATERIAL AND METHODS: Plasma samples taken within the last 24 h before delivery from 135 patients were analyzed, 89 PE and 46 normal pregnancies. All samples were analyzed for cell-free fetal hemoglobin (HbF), heme, hemopexin enzymatic activity (Hx activity), hemopexin concentration (Hx), and heme oxygenase 1 concentration (HO-1). Logistic regression analysis with ROC-curve analysis was performed to evaluate the possible use as biomarkers for preeclampsia. RESULTS: There were significantly higher levels of HbF (p = 0.01) and heme (0.01) but significantly lower Hx activity (p = 0.02), Hx (p < 0.0001) and HO-1 (p = 0.03) in PE plasma as compared to plasma of normal pregnancies. The Hx activity was significantly inversely correlated (p = 0.04) to the diastolic blood pressure. The HO-1 concentration was significantly inversely correlated to both the systolic and diastolic blood pressure (p = 0.01 and p = 0.003). ROC-curve analysis showed a combined detection rate for these biomarkers of 84% at 10% false positive rate. CONCLUSIONS: Increased maternal plasma levels of heme and HbF in PE are associated with decreased HO-1 and hemopexin protein levels as well as reduced hemopexin activity. By measuring the consumption of the scavenger protein Hx, and the proteins in the Hb degradation system, clinical information about the dynamics of the disease can be obtained.
Authors: Karl A Nath; Joseph P Grande; John D Belcher; Vesna D Garovic; Anthony J Croatt; Matthew L Hillestad; Michael A Barry; Meryl C Nath; Raymond F Regan; Gregory M Vercellotti Journal: Am J Physiol Heart Circ Physiol Date: 2020-01-31 Impact factor: 4.733
Authors: Tianyanxin Sun; Giovanna I Cruz; Nima Mousavi; Ivana Marić; Alina Brewer; Ronald J Wong; Nima Aghaeepour; Nazish Sayed; Joseph C Wu; David K Stevenson; Stephanie A Leonard; Melissa Gymrek; Virginia D Winn Journal: Reprod Sci Date: 2022-06-13 Impact factor: 2.924
Authors: Shilong Li; Zichen Wang; Luciana A Vieira; Amanda B Zheutlin; Boshu Ru; Emilio Schadt; Pei Wang; Alan B Copperman; Joanne L Stone; Susan J Gross; Yu-Han Kao; Yan Kwan Lau; Siobhan M Dolan; Eric E Schadt; Li Li Journal: NPJ Digit Med Date: 2022-06-06
Authors: Katja Murtoniemi; Grigorios Kalapotharakos; Tero Vahlberg; Katri Räikkonen; Eero Kajantie; Esa Hämäläinen; Bo Åkerström; Pia M Villa; Stefan R Hansson; Hannele Laivuori Journal: PLoS One Date: 2019-12-16 Impact factor: 3.240
Authors: Amanda Kristiansson; Magnus Gram; Johan Flygare; Stefan R Hansson; Bo Åkerström; Jill R Storry Journal: Int J Mol Sci Date: 2020-09-30 Impact factor: 5.923